The feasibility,effectiveness and safety of totally thoracoscopic resection for right atrial myxoma

Background Myxoma is the most frequent cardiac benign tumor which requires surgical removal even though in right atrium. Minimally invasive surgery has become the standard approach for removal of myxoma in our center. Herein, we report our initial experience of cardiac myxoma removal through mini-port totally thoracoscopic particular with focus on its feasibility, efficacy and short-term outcomes, as compared with median sternotomy. Methods From April 2015 to March 2019, 31 consecutive cases were ultimately identified and divided into two groups(Mini-port thoracoscopic group, n=14; versus conventional median sternotomic group, n=17). An echocardiography was routinely performed prior to discharge, at 1 st month, 6 th month, 12 th month and every year postoperatively. Retrospective analyses of perioperative data, postoperative outcomes and complications,and follow up data were performed. Results All the 31 patients successfully underwent right atrial myxoma removal surgery with no perioperative death, re-exploration for bleeding, residual mass or central nervous event in both groups. Intraoperative data from two group showed absence of significant difference except the intraoperative blood loss(150±50.01 m L in mini-port thoracoscopic group vs. 255.88±93.35 m L in conventional median sternomtomic group, P=0.01). There was no significant difference in perioperative blood transfusion and postoperative outcomes between the two groups. But the mini-port thoracoscopic group had a much less 24-hour postoperative drainage(136.71±148.20 m L vs. 341.17±211.29 m L, P=0.03). No significance difference could be identified between two groups about the incidence of postoperative morbidities and follow-up adverse events. Conclusion Totally mini-port video-assisted thoracoscopic approach for right atrial myxoma resection on peripheral cardiopulmonary bypass is feasible, effective with favorable safety in experienced cardiac center.[S Chin J Cardiol 2019;20(4):236-244]     

Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial

Purpose

To determine whether erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of self-propelled spiral nasoenteric tubes (NETs) in critically ill patients.

Methods

A prospective, multicenter, open-label, parallel, and non-inferiority randomized controlled trial was conducted comparing erythromycin with metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients admitted to intensive care units (ICUs) of eight tertiary hospitals in China. The primary outcome was procedure success defined as post-pyloric placement (spiral NETs reached the first portion of the duodenum or beyond confirmed by abdominal radiography 24 h after tube insertion).

Results

A total of 5688 patients were admitted to the ICUs. Of these, in 355 patients there was a plan to insert a nasoenteric feeding tube, of whom 332 were randomized, with 167 patients assigned to the erythromycin group and 165 patients assigned to the metoclopramide group. The success rate of post-pyloric placement was 57.5% (96/167) in the erythromycin group, as compared with 50.3% (83/165) in the metoclopramide group (a difference of 7.2%, 95% CI ??3.5% to 17.9%), in the intention-to-treat analysis, not including the prespecified margin of ??10% for non-inferiority. The success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond), and proximal jejunum placement and the incidence of any adverse events were not significantly different between the groups.

Conclusions

Erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients. The success rates of post-D1, post-D2, post-D3, and proximal jejunum placement were not significantly different.

     

Functional pasta consumption in healthy volunteers modulates ABCG1-mediated cholesterol efflux capacity of HDL

Backgrounds and aimsPrevention of cardiovascular (CV) disease is considered a central issue in public health and great attention is payed to nutritional approaches, including consumption of functional foods to reduce CV risk in individuals without indications for anti-atherosclerotic drugs. Cholesterol efflux capacity (CEC) is an important anti-atherogenic property of HDL and a marker of CV risk. We evaluated the effect of a daily consumption of an innovative whole-wheat synbiotic pasta, compared to a control whole-wheat pasta, on serum ATP binding cassette G1 (ABCG1)-mediated CEC in healthy overweight or obese individuals.Methods and resultsStudy participants (n = 41) were randomly allocated to either innovative or control pasta, consumed daily for twelve weeks. Serum CEC was measured before and after the dietary intervention, by a well-established radioisotopic technique on Chinese Hamster Ovary Cells transfected with human ABCG1. The innovative synbiotic pasta consumption was associated to a significantly higher post treatment/baseline ratio of ABCG1-mediated CEC values with respect to control pasta (mean ratio 1.05 ± 0.037 and 0.95 ± 0.042 respectively, p < 0.05). Analysis of the relationship between ABCG1-mediated CEC and glycemia, homocysteine, total folates and interleukin-6 showed specific changes in the correlations between HDL function and glycemia, oxidative and inflammatory markers only after synbiotic pasta consumption.ConclusionThis is the first report on serum CEC improvement obtained by a new synbiotic functional pasta consumption, in absence of lipid profile modifications, in overweight/obese participants. This pilot study suggests that a simple dietary intervention can be a promising approach to CV preservation through improving of athero-protective HDL function.     

体外膜肺氧合技术在人工心脏瓣膜置换术后泵衰竭中的应用

目的研究心脏瓣膜置换术后泵衰竭应用体外膜肺氧合(extra corporeal membrane oxygenation,ECMO)支持治疗的效果,为重症心脏瓣膜病患者围术期循环辅助管理提供参考。方法选取东莞康华医院2012年3月至2018年8月收治的心脏瓣膜置换术患者867例,其中18例患者术后出现泵衰竭应用ECMO继续进行循环支持治疗的资料。观察分析患者血浆乳酸、脑钠肽(brain natriuretic peptide,BNP)、肌酐浓度、血管活性药物:肾上腺素及多巴胺使用剂量和心指数在ECMO建立时、运行24 h及撤机时的变化。结果18例泵衰竭应用ECMO支持治疗的心脏瓣膜置换术后患者的血浆乳酸、BNP、肌酐浓度及肾上腺素、多巴胺药物使用剂量在应用ECMO支持治疗即时、运行24 h及停止时呈现显著降低趋势,而心指数则出现逐步升高趋势,差异有统计学意义(P<0.05)。围术期因ECMO严重并发症导致多器官功能衰竭而死亡6例。结论应用ECMO支持治疗人工心脏瓣膜置换术后泵衰竭,可有效辅助治疗循环衰竭,进而降低外科换瓣患者手术死亡率。